BACKGROUND: Human immunodeficiency virus (HIV)-infected persons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated. METHODS: The impact of PPV vaccination on the incidence of pneumonia events (i.e., the composite of pneumococcal pneumonia and pneumonia due to nonspecified organisms) was examined among participants in the Veterans Aging Cohort 5-Site Study, an ongoing prospective study of HIV-infected patients matched to an HIV-uninfected control group. Dates of PPV vaccination and pneumonia were determined by retrospective review of electronic medical records. Time to events was measured for up to 2 years from PPV vaccination or from enrollment for vaccinated and unvaccinated patients, respectively. Kaplan-Meier and Cox proportional hazards regression methods were used to examine the incidence of pneumonia by HIV infection and PPV vaccination status. RESULTS: Among 692 HIV-uninfected and 934 HIV-infected study participants, 59% were vaccinated with PPV. The 2-year incidence of pneumonia was 6% (97 participants developed pneumonia). HIV-infected patients had a higher rate of pneumonia (hazard ratio, 5.81; 95% confidence interval, 3.15-10.71); overall, vaccinated patients showed a trend toward lower risk of pneumonia (hazard ratio, 0.75; 95% confidence interval, 0.50-1.13). Among HIV-infected patients, after controlling for HIV-specific and other variables, vaccination significantly reduced the risk of pneumonia (hazard ratio, 0.65; 95% confidence interval, 0.42-1.00); current smoking, low hemoglobin level, and low CD4 cell count significantly increased such risk. The effect of PPV vaccination among HIV-uninfected patients was not significant. CONCLUSIONS: Among HIV-infected patients, PPV vaccination offered protection against pneumonia. Smoking cessation needs to be pursued as an additional strategy for preventing pneumonia.
BACKGROUND: Human immunodeficiency virus (HIV)-infectedpersons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated. METHODS: The impact of PPV vaccination on the incidence of pneumonia events (i.e., the composite of pneumococcal pneumonia and pneumonia due to nonspecified organisms) was examined among participants in the Veterans Aging Cohort 5-Site Study, an ongoing prospective study of HIV-infectedpatients matched to an HIV-uninfected control group. Dates of PPV vaccination and pneumonia were determined by retrospective review of electronic medical records. Time to events was measured for up to 2 years from PPV vaccination or from enrollment for vaccinated and unvaccinated patients, respectively. Kaplan-Meier and Cox proportional hazards regression methods were used to examine the incidence of pneumonia by HIV infection and PPV vaccination status. RESULTS: Among 692 HIV-uninfected and 934 HIV-infected study participants, 59% were vaccinated with PPV. The 2-year incidence of pneumonia was 6% (97 participants developed pneumonia). HIV-infectedpatients had a higher rate of pneumonia (hazard ratio, 5.81; 95% confidence interval, 3.15-10.71); overall, vaccinated patients showed a trend toward lower risk of pneumonia (hazard ratio, 0.75; 95% confidence interval, 0.50-1.13). Among HIV-infectedpatients, after controlling for HIV-specific and other variables, vaccination significantly reduced the risk of pneumonia (hazard ratio, 0.65; 95% confidence interval, 0.42-1.00); current smoking, low hemoglobin level, and low CD4 cell count significantly increased such risk. The effect of PPV vaccination among HIV-uninfectedpatients was not significant. CONCLUSIONS: Among HIV-infectedpatients, PPV vaccination offered protection against pneumonia. Smoking cessation needs to be pursued as an additional strategy for preventing pneumonia.
Authors: R F Breiman; D W Keller; M A Phelan; D H Sniadack; D S Stephens; D Rimland; M M Farley; A Schuchat; A L Reingold Journal: Arch Intern Med Date: 2000-09-25
Authors: N French; J Nakiyingi; L M Carpenter; E Lugada; C Watera; K Moi; M Moore; D Antvelink; D Mulder; E N Janoff; J Whitworth; C F Gilks Journal: Lancet Date: 2000-06-17 Impact factor: 79.321
Authors: S Moir; A Malaspina; K M Ogwaro; E T Donoghue; C W Hallahan; L A Ehler; S Liu; J Adelsberger; R Lapointe; P Hwu; M Baseler; J M Orenstein; T W Chun; J A Mican; A S Fauci Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: D M Musher; I Alexandraki; E A Graviss; N Yanbeiy; A Eid; L A Inderias; H M Phan; E Solomon Journal: Medicine (Baltimore) Date: 2000-07 Impact factor: 1.889
Authors: Krishanthi S Subramaniam; Robert Segal; Robert H Lyles; Maria C Rodriguez-Barradas; Liise-anne Pirofski Journal: J Infect Dis Date: 2003-02-24 Impact factor: 5.226
Authors: Lisa A Jackson; Kathleen M Neuzil; Onchee Yu; Patti Benson; William E Barlow; Annette L Adams; Christi A Hanson; Lisa D Mahoney; David K Shay; William W Thompson Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Engi F Attia; Kathleen A McGinnis; Laura C Feemster; Kathleen M Akgün; Adeel A Butt; Christopher J Graber; Michael J Fine; Matthew B Goetz; Maria C Rodriguez-Barradas; Margaret A Pisani; Hilary A Tindle; Sheldon T Brown; Guy W Soo Hoo; David Rimland; Cynthia L Gibert; Laurence Huang; Matthew S Freiberg; Catherine L Hough; Kristina Crothers Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731
Authors: S L Pett; C Carey; E Lin; D Wentworth; J Lazovski; J M Miró; F Gordin; B Angus; M Rodriguez-Barradas; R Rubio; G Tambussi; D A Cooper; S Emery Journal: HIV Med Date: 2010-08-31 Impact factor: 3.180